Suboptimal LDL ‐Cholesterol Control Under the 2019 ESC / EAS Dyslipidemia Guidelines: Results From the Nationwide TEMD ‐2 Study in Type 2 Diabetes
Authors' conclusion
Three years after the implementation of the 2019 dyslipidemia guidelines, patients with type 2 diabetes remain far from achieving LDL-C targets, with fewer than one in ten reaching target levels.
Study context
- Population
- Adults with T2D followed in 70 tertiary endocrine clinics across 36 cities in Turkey, October 2022–January 2023
- Participants
- 4,956 adults
- Outcome
- LDL-C target attainment according to 2019 ESC/EAS guideline cardiovascular risk categories
Methodological detailsmulticenter, nationwide
- Multicenter
- Nationwide
Main finding
As reported in the abstract
LDL-C target achievement
Overall cohort achieving LDL-C targets
8.3%
Very-high-risk patients achieving LDL-C target
5.8%
Observational data: associations, not effects.
Further findings
Statin therapy need and use
- Required statin therapy
- 99.5%
- On statin treatment
- 37.1%
LDL-C target achievement among statin users, by risk category
- Moderate risk
- 57.7%
- High risk
- 18.1%
- Very high risk
- 9.4%
Predictors of LDL-C goal attainment (multivariable logistic regression)
- Statin therapy, strongest positive predictor (OR)
- 2.39
- Smoking, neuropathy, nephropathy, female sex, older age and higher haemoglobin A1c (HbA1c) associated with lower likelihood of achieving LDL-C goals
- Patients on target had lower BMI, HbA1c, TG and lower prevalence of microvascular complications
Therapeutic inertia (no intensification of lipid-lowering therapy despite LDL-C above target)
- Therapeutic inertia
- 87.2%
Original publication
Suboptimal LDL ‐Cholesterol Control Under the 2019 ESC / EAS Dyslipidemia Guidelines: Results From the Nationwide TEMD ‐2 Study in Type 2 Diabetes. Diabetes Obes Metab. Published 6 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →